Rapid-acting insulin glulisine: a new tool for postprandial glucose control

References

• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care27, 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA290, 1884–1890 (2003).
   PubMed Web of Science ®Google Scholar
• Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with Type 2 diabetes. Diabetes Care27, 17–20 (2004).
   PubMed Web of Science ®Google Scholar
• The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.329, 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract.28, 103–117 (1995).
   PubMed Web of Science ®Google Scholar
• Ceriello A. Posprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes54, 1–7 (2005).
   PubMed Web of Science ®Google Scholar
• Monnier L, Lapinski H, Collette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA1C. Diabetes Care26, 881–885 (2003).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care28, S4–S36 (2005).
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists. Consensus statement on guidelines for glycemic control. Endocr. Prac.8(Suppl. 1), 5–11 (2002).
   PubMedGoogle Scholar
• Esposito K, Giugliano D, Nappo F, Marfella R (The Companian Postprandial Hyperglycemia Study Group). Regression of carotid atherosclerosis by control of postprandial hyperglycemia in Type 2 diabetes mellitus. Circulation110, 214–219 (2004).
   PubMed Web of Science ®Google Scholar
• Owens D, Zinman B, Bolli G. Insulins today and beyond. Lancet358, 739–746 (2001).
   PubMed Web of Science ®Google Scholar
• DeWitt DE, Hirsch IB. Outpatient insulin therapy in Type 1 and Type 2 diabetes mellitus: a scientific review. JAMA289, 2254–2264 (2003).
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR, UKPDS Study Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA281, 2005–2012 (1999).
   PubMed Web of Science ®Google Scholar
• Wright A, Burden AC, Paisey RB et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with Type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care25, 330–336 (2002).
   PubMed Web of Science ®Google Scholar
• Butler AE, Janson J, Bonner-Weir S et al. β-cell deficit and increased β-cell apoptosis in humans with Type 2 diabetes. Diabetes52, 102–110 (2003).
   PubMed Web of Science ®Google Scholar
• Writing Team for the DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of Type 1 diabetes mellitus. JAMA287, 2563–2569 (2002).
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med.342, 381–389 (2000).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Lachin J, Cleary P et al (and the Epidemiology of Diabetes Interventions and Complications Research Group). Intensive diabetes therapy and carotid intima-media thickness in Type 1 diabetes mellitus. N. Engl. J. Med.348, 2294–2303 (2003).
   PubMed Web of Science ®Google Scholar
• Cleary P, Orchard T, Zinman B (and the DCCT/EDIC Study Group). Coronary calcification in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Presented at: 63rd Annual Scientific Sessions of the American Diabetes Association. New Orleans, LA, June 13–17 (2003).
   Google Scholar
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventios and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med.353, 643–653 (2005).
   Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature414, 813–820 (2001).
   PubMed Web of Science ®Google Scholar
• Larme AC, Pugh JA. Attitudes of primary care providers toward diabetes: barriers to guideline implementation. Diabetes Care21, 1391–1396 (1998).
   PubMed Web of Science ®Google Scholar
• Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab. Res. Rev.15, 42–46 (1999).
   PubMed Web of Science ®Google Scholar
• Hirsch IB. Insulin analogues. N. Engl. J. Med.352, 174–183 (2005).
   PubMed Web of Science ®Google Scholar
• Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in Type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr. Pract.11, 1–7 (2005).
   PubMedGoogle Scholar
• Rakatzi I, Seipke G, Eckel J. [LysB3, GluB29] insulin: a novel insulin analog with enhanced β-cell protective action. Biochem. Biophys. Res. Commun.310, 852–859 (2003).
   PubMed Web of Science ®Google Scholar
• Becker RHA, Frick AD, Burger F, Potgieter JH, Scholtz H. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp. Clin. Endocrinol. Diabetes.113, 435–443 (2005).
   PubMed Web of Science ®Google Scholar
• Rakatzi I, Ramrath S, Ledwig D et al. A novel insulin analog with unique properties LysB3, GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes52, 2227–2238 (2003).
   PubMed Web of Science ®Google Scholar
• Insulin glulisine: treatment of Type 1 and Type 2 diabetes. Drugs Future28, 1055–1058 (2003).
   Google Scholar
• American Diabetes Association. Postprandial blood glucose. Diabetes Care24, 775–778 (2001).
   PubMed Web of Science ®Google Scholar
• Ceriello A, Hanefeld M, Leiter L et al. Postprandial glucose regulation and diabetic complications. Arch. Intern. Med.164, 2090–2095 (2004).
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (The STOP–NIDDM Trial Research Group). Acarbose for prevention of Type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet359, 2072–2077 (2002).
   PubMed Web of Science ®Google Scholar
• The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet354, 617–621 (1999).
   PubMed Web of Science ®Google Scholar
• Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in Type 2 diabetic patients. Diabetes Care23(Suppl. 2), B21–B29 (2000).
   PubMed Web of Science ®Google Scholar
• Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch. Intern. Med.163, 1306–1316 (2003).
   PubMed Web of Science ®Google Scholar
• Erlinger T, Brancati F. Postchallenge hyperglycemia in a national sample of US adults with Type 2 diabetes. Diabetes Care24, 1734–1738 (2001).
   PubMed Web of Science ®Google Scholar
• Apidra®, prescribing information. Aventis Pharmaceuticals Kansas City, MO, USA (2004).
   Google Scholar
• Becker RHA, Frick AD, Burger, F, Scholtz H, Potgieter JH. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp. Clin. Endocrinol. Diabetes.113, 292–297 (2005).
   PubMed Web of Science ®Google Scholar
• Becker R, Frick A, Burger F, Scholtz H. Pharmacodynamics and pharmacokinetics of a new, rapidly-acting insulin analog, insulin glulisine. Diabetes52(Suppl. 1), A110 (2003).
   Google Scholar
• Heise T, Nosek L, Heinemann L et al. Consistent fast onset of action and absorption of glulisine in lean to obese subjects. Diabetes54(Suppl. 1), A145 (2005).
   Google Scholar
• Jaros M, Martinek V, Piechatzek R, Frick A, Becker R. Pharmacokinetics of insulin glulisine in non-diabetic renally impaired patients. Diabetes53(Suppl. 2), A321 (2004).
   PubMed Web of Science ®Google Scholar
• Rave K, Nosek L, Heinemann L, Frick A, Becker R. Insulin glulisine: pharmacokinetic and pharmacodynamic properties in comparison with insulin lispro and regular human insulin in Japanese and Caucasian volunteers. Diabetes53(Suppl. 2), A143 (2004).
   Google Scholar
• Danne T, Becker RHA, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with Type 1 diabetes. Diabetes Care28, 2100–2105 (2005).
   PubMed Web of Science ®Google Scholar
• Nosek L, Becker R, Frick A, Kapitza C, Heise T, Rave K. Prandial blood glucose control with pre- and post-meal insulin glulisine versus regular human insulin. Diabetes53(Suppl. 2), A139 (2004).
   Google Scholar
• Becker R, Frick A, Kapitza C, Heise T, Rave K. Pharmacodynamics and pharmacokinetics of insulin glulisine compared with insulin lispro and regular human insulin in patients with Type 2 diabetes. Diabetes53(Suppl. 2), A119 (2004).
   Google Scholar
• Dailey G, Rosenstock J, Moses R, Ways K. Insulin glulisine provides improved glycemic control in patients with Type 2 diabetes. Diabetes Care27, 2263–2268 (2004).
   Google Scholar
• Dreyer M, Prager R, Robinson A et al. Efficacy and safety of insulin glulisine in patients with Type 1 diabetes. Horm. Metab. Res.37, 702–707 (2005).
   PubMed Web of Science ®Google Scholar
• Hanaire-Broutin H, Schumicki D-M, Hoogma RP, Souhami E. Safety of insulin glargine compared with insulin aspart administered by continuous subcutaneous insulin infusion (CSII). Diabetes53(Suppl. 2), A4 (2004).
   Google Scholar
• Symlin®, prescribing information. Amylin Pharmaceuticals, San Diego, CA, USA (2005).
   Google Scholar
• Byetta®, prescribing information. Amylin Pharmaceuticals, San Diego, CA, USA (2005).
   Google Scholar